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ABSTRACT
Increasing evidence suggests that cancer cell populations contain a small proportion of cells
that display stem-like cell properties and which may be responsible for overall tumor mainte-
nance. These cancer stem-like cells (CSCs) appear to have unique tumor-initiating ability and
innate survival mechanisms that allow them to resist cancer therapies, consequently promoting
relapses. Selective targeting of CSCs may provide therapeutic benefit and several recent reports
have indicated this may be possible. In this article, we review drugs targeting CSCs, in selected
epithelial cell-derived cancers. STEM CELLS 2017;35:839–850
SIGNIFICANCE STATEMENT
Drugs selectively targeting cancer stem-like cells (CSC) continues to evolve, and hold significant
promise for the next phase of cancer therapeutics. This review article highlights recent achieve-
ments in our understanding of CSC signaling and its mediators and summarizes advances in the
discovery and development of targeted therapy and novel therapeutics/drugs making their way
to the clinic. We focused on the unique challenges of working with epithelial cell-derived CSC,
including the characterization of cell populations, the identification of druggable targets and
pathways, their validation in preclinical models, and the translation to the clinic.
INTRODUCTION
Cancer stem-like cells (CSCs) are a subpopula-
tion of tumor cells that have the extraordinary
characteristic of self-renewal and the ability to
generate cellular heterogeneity within a tumor
[1–3]. These cells possess a number of distinc-
tive features that allow them to become resis-
tant to anticancer therapies and tumor-targeted
drugs, which in turn, helps them to survive
treatment and initiate tumor recurrence [3].
CSCs are immortal tumor-initiating cells with
multipotent capacity. They are a major driving
factor for tumor development, progression,
metastasis, resistance to chemotherapy, and
relapses after cancer treatment [1, 3, 4].
Over the last three decades, treatment options
including chemotherapy, surgery and radiotherapy
have only made incremental improvements in
terms of patients survival [5]. Chemotherapy and
radiotherapy primarily target differentiated and
proliferating cancer cells while being less effective
in targeting the relatively undifferentiated and qui-
escent CSCs [6, 7]. Many novel anticancer drugs,
including tyrosine kinase inhibitors and monoclo-
nal antibodies (mAbs) reduce the tumor size but
fail to eliminate CSCs, which has been associated
with cancer recurrence [8, 9].
Emerging evidence also indicates that some
conventional anticancer drugs not only fail to
eliminate CSCs [10, 11], but selectively enrich
CSCs [7, 12, 13] possibly by inducing dedifferen-
tiation or trans-differentiation [6, 7]. For exam-
ple, in breast cancer patients receiving systemic
chemotherapy, breast tumors show strong selec-
tion for CSC survival and expansion [14, 15]. This
was demonstrated by increased CD44hi/CD24lo
marker proﬁle and increased sphere-forming
ability in breast cancer after conventional che-
motherapy treatment with paclitaxel [15, 16].
Such observations on existing cancer treatments
underline the need for a strategy based on selec-
tively targeting of CSCs [17] (Fig. 1). In this arti-
cle, we review the recent developments on new
drugs targeting for CSCs, with a focus on major
epithelial-derived cancers.
SELECTIVE TARGETING OF CSCS
Selective targeting of CSC is a huge challenge
from the therapeutic point of view as strate-
gies that are not sufﬁciently selective for CSCs
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CANCER STEM CELLS
may cause toxicity to healthy tissues and increase risk of recur-
rence among the patients [18]. Many approaches exploit the dif-
ferences in cell surface markers to identify compounds that
selectively target CSCs. These targets include the ATP binding cas-
sette (ABC) transporter superfamily, anti-apoptotic factors, detox-
ifying and DNA repair enzymes and distinct oncogenic cascades
such as Wnt/b-catenin, TGF-b, Hedgehog (Hh), EGFR, PTEN, BMI-
1, NF-jB, Bcl-2, JAK/STAT, Notch, and PI3K/Akt/mTOR pathways
[1, 19–22]. Compounds that preferentially induce the terminal
differentiation of CSCs may also provide a valid therapeutic ratio-
nale for eliminating CSCs. For example, in humans, both normal
breast and breast cancer stem cells express the OCT4 gene but
neither express the connexin 43 gene. These two genes serve
two diametrically opposed functions. OCT4 maintains the stem-
ness and undifferentiated state of both normal and breast CSCs,
while expression of connexin 43 gene is required for differentia-
tion [23]. Selective expression of OCT4 and connexin 43 genes
may be exploited to induce the CSCs to terminally differentiate.
Recently, several compounds have been identiﬁed to tar-
get CSCs, a combination of which with conventional chemo-
therapy drugs has been shown to signiﬁcantly suppress self-
renewal, induce differentiation, inhibit tumor growth and
metastasis, and eventually eliminate CSCs [19, 24] (Fig. 1).
Table 1 shows the clinical status of some drugs and com-
pounds identiﬁed for targeting of CSCs in different cancers.
BREAST CANCER
Signaling pathways such as Notch, Wnt, and Hh have received
much interest as key targets for CSC-based therapies in breast
cancer [49]. The Wnt/b-catenin pathway is essential for CSC
survival, self-renewal and resistance, and downregulating this
pathway has been shown to eliminate CSCs in breast cancer
cells [50, 51]. Oxymatrine and curcumin downregulated Wnt1,
b-catenin, c-Myc, and Cyclin D1 in MCF-7 and MDA-MB-231
human breast cancer cells, causing inhibition of self-renewal
and “tumorsphere” formation [3, 42]. The antitumor effect of
curcumin was conﬁrmed in vivo in a nude mouse model bear-
ing MDA-MB-231 xenograft tumors [52]. Given their safety
proﬁle, curcumin and oxymatrine, may constitute promising
candidates for breast cancer therapy, although additional
studies are needed to validate this therapeutic approach.
Breast CSCs exhibit increased Notch expression, and at pre-
sent, anti-Notch mAbs and g-secretase inhibitors (GSI) are under
clinical evaluation for advanced breast cancer [53]. Targeting the
Notch pathway has been reported to reduce stem-like cell activi-
ty in vitro using breast-cancer-derived secondary mammo-
spheres, and patient-derived tumor formation in vivo [54]. Upon
combination with docetaxel, both mAbs and GSIs enhance the
efﬁcacy of docetaxel and reduce self-renewal and tumor growth.
This effect was particularly seen in patient-derived xenografts
obtained from the Sum149 triple-negative breast cancer (TNBC)
cell line and TNBC primary cancer cells [21, 24, 54]. Patients with
TNBC have an exceptionally poor prognosis. While current treat-
ments with doxorubicin and cyclophosphamide fail to eradicate
CSCs and lead to recurrence within 4-6 weeks [3, 43], inhibition
of self-renewal by mAbs or GSI may provide an effective strategy
against this aggressive form of cancer.
A number of other studies suggest that metformin may
selectively target breast CSCs. For example, metformin
Figure 1. Different approaches in cancer treatment. (1) Recurrence of cancer by the remaining CSCs after conventional cancer treat-
ment. (2) CSC-targeted therapies will (A) eliminate both CSCs and NSCs and cause loss of cancer progression, and (B) induce differentia-
tion to CSCs and make them susceptible to conventional cancer therapy. This approach, when combined with conventional cancer
treatment will result in regression of cancer without affecting the NSCs. Abbreviations: CSCs, cancer stem-like cells; NSC, normal stem-
like cells.
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Table 1. Drugs and novel compounds identiﬁed for selective cancer stem-like cells targeting
Compound Mode of actions/targets Cancer types Clinical status References
3-O-methylfunicone
(OMF)
Inhibits CD24, CD29, CD44, CD133,
CD338; reduces Survivin,
hTERT and Nanog
Breast CSC Preclinical [3, 25]
BBI503 Stemness kinase inhibitor Advanced colorectal CSC Phase 1/2 [26]
BBI608 STAT3 inhibitor Colorectal CSC Phase 3 [27]
Berberine Quaternary ammonium salt Breast CSC, colorectal CSC Phase 2/3 [28]
Catumaxomab
(anti-EpCAM/
anti-CD3)
Bispeciﬁc antibody CSCs in malignant ascites induced
by human ovarian, gastric and
pancreatic cancer
Phase 1/3 [3]
Cyclopamine, Smo antagonist, Hedgehog
pathway inhibitor
Glioblastoma CSC, multiple myelo-
ma CSC, chronic myeloid leuke-
mia SC, gastric CSC, breast CSC,
prostate CSC, pancreatic CSC
Phase 1 [3, 29]
Curcumin, analog
GO-Y030, diﬂurinated
curcumin (CDF)
Wnt inhibitor; affects many CSC
regulators (Hedgehog, Notch,
PI3K/Akt/mTOR pathway.
Glioblastoma SC, colon CSC, pancre-
atic CSC, breast CSC
Phase 2 [3, 30]
Epigallocatechin gallate
(EGCG) and its
synthetic analogs
Downregulates mTOR pathway;
activates AMPK and
upregulates p21
Prostate CSC, pancreatic CSC, breast
CSC, advanced solid tumors, SCLC
Phase 1/2 [3, 31]
G007-LK Wnt inhibitor Colorectal CSC Preclinical [32]
G244-LM Wnt inhibitor Colorectal CSC Preclinical [32]
Genistein Wnt inhibitor Colon CSC Phase 2 [33]
IWR-1 Wnt inhibitor NSCLC, colorectal CSC Preclinical [32]
JW55 Wnt inhibitor Colorectal CSC Preclinical [32]
LDE-225a Hedgehog inhibitor SCLC CSC, pancreatic CSC, breast
CSC, basal cell carcinoma
Phase 1 [34, 35]
LGK974 Porcupine inhibitor Colorectal CSC Phase 1 [36]
Metformin Reduces EMT related ZEB1,
TWIST1 and Slug
Breast CSC, pancreatic CSC, thyroid
CSC, prostate CSC, solid tumors
Phase 1/3 [23, 37, 38]
Mithramycin Telomerase inhibitor Lung CSC,gastrointestinal CSC,
Breast CSC
Phase 2 [39]
MT110 (Anti-EpCAM/anti-CD3) bispeciﬁc
antibody
Colon CSC, pancreatic CSC,
advanced solid tumors
Phase 1 [40]
OMP-21M18 Anti-DLL4 monoclonal antibody NSCLC-SC, colon CSC, breast CSC Phase 1 [41]
OMP-18R5 Frizzled 21, 22, 25, 27, 28 receptors Intestinal solid tumor Phase 1 [36]
Oxymatrine Downregulates Wnt1, b-catenin, c-Myc,
Cyclin D1, LEF1.
Breast CSC Preclinical [3, 42]
P245 Anti-CD44 monoclonal antibody Breast CSC Preclinical [43]
Parthenolide,
dimethylaminoparthenolide
LC1
NF-B inhibitor, targets proto-oncogene
tyrosine protein kinase Src
AML-SC, lymphoid leukemia SC,
breast CSC, prostate CSC, myelo-
ma-SC
Phase 1 [3]
PRI-724 CBP/Catenin antagonist Advanced intestinal solid tumor SC Phase 1 [36]
PTC-596 BMI-1 inhibitor Advanced solid tumor SC Phase 1 [44]
Resminostat HDAC inhibitor Advanced colorectal CSC Phase1/2 [45]
Repertaxin CXR1 and CXR2 inhibitor Breast CSC Preclinical [3]
Resveratrol Wnt inhibitor; upregulates
miR622 and miR633
Medulloblastoma SC, breast CSC,
pancreatic CSC, glioblastoma SC
Phase 1/2 [46]
Salinomycin Inhibits ALDH, SOX2, CXCR4;
reduces CD133, vimentin;
induces E-cadherin
Breast CSC, AML SCs, GIST SC, gas-
tric CSC, lung CSC, osteosarcoma
SC, colorectal CSC, squamous cell
carcinoma SC, prostate CSC, pan-
creatic CSC
Phase 1/2 [22]
Sulforaphane Wnt inhibitor Pancreatic CSC, breast CSC, prostate
CSC, CML SC
Preclinical [3, 47]
TG4010 Recombinant vaccine NSCLC SC Phase 2/3 [32]
Tranilast Agonist for AHR; decreases Oct4,
CD133
Breast CSC Preclinical [3]
Vismodegib (GDC 0449) Smo antagonist, Hedgehog
inhibitor
Pancreatic CSC, lung CSC, medullo-
blastoma, basal cell carcinoma,
glioblastoma, chondrosarcoma,
gastric carcinoma colon, ovarian,
breast CSC
Phase 1/2 [3, 48]
WIKI4 Wnt inhibitor Colon CSC Preclinical [32]
XAV939 Tankyrase inhibitor Colon CSC Phase 1 [33]
aFDA approved for basal cell carcinoma.
Abbreviations: EMT, epithelial-mesenchymal transition; miRs, microRNAs; HDAC, histone deacetylase; NSClC, non-small cell lung cancer; SCLC,
small cell lung cancer.
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resensitized MCF-7 breast CSCs to radiation [55]. Metformin also
caused signiﬁcant inhibition in both self-renewal and CSCs prolif-
eration in MCF-7-derived mammospheres that are enriched for
CD441/CD242/low CSC populations [23]. Furthermore, metfor-
min reduced expression of epithelial-mesenchymal transition
(EMT)-related gene products like ZEB1, TWIST1, and SLUG in
CD441/CD242/low CSCs from four other breast cancer cell lines
[37]. The selective effect of metformin on CSCs contrasted with a
commonly used anticancer drug, doxorubicin. Doxorubicin signif-
icantly killed cancer cells but spared the CSCs [56]. When com-
bined with metformin, doxorubicin caused a reduction in both
cancer cells and CSCs from the heterogeneous tumor population,
indicating the effectiveness of combination therapy [56]. In
another study, metformin was shown to suppress the self-
renewal and proliferation of trastuzumab-resistant human breast
CSCs, and to act synergistically with trastuzumab in vitro [37].
Moreover, metformin also showed signiﬁcant anti-TNBC effects
both in vitro and in vivo. For example, MDA-MB-231 cell derived
xenografts showed signiﬁcant reduction in tumor outgrowth
upon pretreatment with metformin [57].
Selective targeting of breast CSCs was also observed with
salinomycin. Salinomycin inhibited mammary tumor growth in
vivo and induced epithelial differentiation of tumor cells [15].
Compared to paclitaxel, salinomycin was 10-fold more potent
in decreasing the number of tumorspheres and 100-fold more
potent in reducing the CSC population in breast cancer cell
lines [15]. More importantly, it enhanced the cytotoxicity of
conventional cancer drugs like doxorubicin, gemcitabine, eto-
poside, paclitaxel, docetaxel, vinblastine, and trastuzumab,
suggesting that it is worthwhile to explore and evaluate the
usefulness of salinomycin-based combination therapies for
breast cancer CSCs treatment [22, 58]. The combination of sal-
inomycin with a histone deacetylase (HDAC) inhibitor LBH589
showed synergistic inhibitory effect on TNBC stem-like cells in
vivo. In xenograft mouse models, this combination inhibited
the tumor growth of ALDH1-positive cells by inducing apopto-
sis and cell cycle arrest [59].
Agonists of the retinoic acid receptor and peroxisome
proliferator-activated receptor -g selectively inhibited tumor-
spheres obtained from the MCF7 cell line by suppressing the
activity of the NFjB/IL6 axis which is highly active in breast
cancer derived tumorspheres. By contrast, normal mammary
gland derived tumorspheres or nontumorigenic MCF10 cell
lines were not inhibited [60]. Iinhibition of focal adhesion
kinase (FAK) and related signaling pathways by genetic manipu-
lation caused suppression of tumorigenesis and reduction in
breast CSC progression in vivo [61]. Since these cells possess
intrinsic chemoresistance [62], FAK-inhibitor based therapy may
help to overcome drug resistance, eliminating breast CSCs and
preventing breast cancer recurrence [21]. In this context, an
anti-alcoholism drug disulﬁram has cytotoxic effects in breast
CSCs by interfering with self-renewal, apoptosis and by re-
sensitizing breast CSCs to cytotoxic drugs [63]. Furthermore,
recent studies reported that treatment with azithromycin and
O-methylfunicone (OMF, a metabolite produced by Penicillium
pinophilum) resulted in depletion of tumorsphere formation
and CSCs population in breast cancer cell lines [25, 64]. It was
demonstrated that, in contrast to cisplatin, OMF treatment
caused a marked reduction in both the number and the size of
tumorspheres as judged by the complete disappearance of
CD24, CD29 CD44, CD133, and CD338 in breast CSCs.
Moreover, OMF treatment resulted in induction of apoptosis
and downregulation of Survivin, hTERT and NANOG expression
demonstrating the effectiveness of OMF in selective targeting
in breast CSC [25]. Additionally, recent studies have also sug-
gested that the repertaxin may selectively target human breast
CSC. Repertaxin treatment caused a marked decrease in breast
CSCs population and their sphere-forming ability [65], and
selectively inhibited IL-8 mediated EMT, angiogenesis, metasta-
sis, and chemotherapy resistance in breast cancer [66]. Alto-
gether, these ﬁndings provide evidence for the development of
strategies to target the breast CSCs phenotype.
COLORECTAL CANCER
At present, conventional chemotherapy of colorectal cancer
(CRC) is primarily based on 5-ﬂuorouracil (5-FU), oxaliplatin,
and irinotecan. However, the response rates of CRC to these
chemotherapies are about 40%–50% and in many cases CSCs
can survive the treatment [22]. CRC cells are highly depen-
dent on constitutively active Wnt signaling for cell survival,
growth, and differentiation [36]. CRC-SCs typically have high
levels of b-catenin activity [15]. At present, several therapies
are being evaluated for their ability to inhibit Wnt signaling
[67], destabilize b-catenin or disrupt the b-catenin/TCF [53].
For example, resveratrol inhibits the Wnt pathway in colonic
mucosa and thereby prevents cancer development [46]. It
also downregulates several oncogenic microRNAs (miRs) and
upregulates tumor suppressive miRs like miR-622 and miR-633
[68]. Recent advances also include the development of highly
promising mAbs against the Wnt cascade, Fz receptors, or
secreted Fz-related proteins for clinical use [69, 70].
Besides atypical activation of cellular signaling, CRC-SCs
have been associated with resistance to therapy. Several stud-
ies revealed that the drug resistance of CRC-SCs may be over-
come by pretreatment with HDAC inhibitors such as
vorinostat or romidepsin [45, 71]. Vorinostat is a broad-
spectrum HDAC inhibitor targeting class I, II, and IV HDACs,
whereas romidepsin is a class I HDAC inhibitor. These inhibi-
tors change the level of pro- and anti-apoptotic molecules,
induce cell cycle arrest at G1/S or G2/M transition thereby
enhancing differentiation and apoptosis [45]. Vorinostat and
romidepsin treatment of CRC-SCs resulted in a reduction of
Wnt expression and induced differentiation [71]. Therefore,
these inhibitors may provide a novel way to make the CRC-
SCs more susceptible to conventional chemotherapy [21].
Similar to its effect on breast CSCs, salinomycin also inhib-
ited a number of CRC-SC characteristics including colono-
sphere formation, migration and invasion. It also selectively
reduced the CD1331 cell population by inducing E-cadherin
downregulation and upregulation of vimentin in HT29 CRC
cells [22]. Moreover, salinomycin induced the cytotoxicity and
cell death of CD44 1 EpCAM1 population in HCT116 CRC cells
and in a dose dependant manner, inhibited growth of HCT116
xenografts in mouse models in vivo [72]. As a result, salino-
mycin drug is now in clinical trial phases 1/2 and initial evi-
dence suggests it to be a potential drug for CRC. In recent
years, cellular prion protein (PrPC) has also been considered
as a promising target molecule for cancer therapies and mAbs
targeting CD441 CRC-SCs expressing PrPC1 inhibited metastat-
ic capacity [73].
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Porcupine and interferon (IFN) inhibitors may be used to
target CRC-SCs. Porcupine inhibitors such as LGK974 inhibit
palmitoylation of Wnt and since this is a required step in Wnt
secretion and Wnt action. For example, such effect was medi-
ated by suppression of tumor growth in murine xenografts
established by mouse mammary tumor virus-driven Wnt1
expression [36]. IFN is a cytokine typically used in the treat-
ment of viral diseases and it also has antitumor activity. In
HT29 CRC cells, IFNa has been shown to suppress CRC-SCs
self-renewal [74], by inducing apoptosis and differentiation.
CRC-SCs express the polycomb gene BMI-1, which is asso-
ciated with poor patient outcome and resistance [21]. Treat-
ment of primary CRC-derived xenografts with BMI-1 inhibitors
like PTC-209, resulted in CRC-SCs loss with long-term and irre-
versible impairment of tumor growth [75]. Furthermore, the
AP20187 treatment has increased 5-FU-induced cell death of
CRC-SCs. AP20187 is a synthetic, cell-permeable drug that can
induce dimerization of fusion proteins containing a growth
factor receptor signaling domain. For example, along with
increased apoptosis, a signiﬁcant decrease in tumor size and
CD1331 CRC-SCs loss were observed in mouse models upon
treatment with AP20187 in vivo [76].
Curcumin in combination with the widely used FOLFOX
(Folinic acid, 5-FU, and oxaliplatin) regimen appeared to inter-
fere with CRC-SCs [77]. It affects multiple CSC regulators includ-
ing Wnt/b-catenin, Sonic Hh, Notch and PI3K/Akt/mTOR
signaling, while sensitizing CRC-SCs [78, 79]. Increasing data
suggest that the curcumin in combination therapy is highly
effective in eliminating the CSCs in chemo-resistant colon can-
cer cells. The combination of curcumin and thetyrosine kinase
inhibitor dasatinib, eliminated FOLFOX-resistant CRC-SCs more
efﬁciently than the single agents [80]. Synthetic analogs includ-
ing GO-Y030, GO-YY078 and diﬂuorinated curcumin (CDF) have
been developed to improve the bioavailability of curcumin, and
these showed enhanced tumor suppression in vitro and in vivo
in Apc(580D/1) mice [78]. These ﬁndings suggest that a nontoxic
agent such as curcumin or its analog(s) by itself or together
with the conventional chemotherapeutic could be an effective
treatment strategy for preventing the emergence of chemore-
sistant colon cancer cells by reducing/eliminating CSCs.
LUNG CANCER
Lung cancer is the most lethal form of cancer worldwide.
About 80%-85% of lung cancers are non-small cell lung cancer
(NSCLC). NSCLC grows and spreads more slowly than small
cell lung cancer (SCLC) which makes up 15%-20% of the lung
cancer cases. With the existing treatment options for lung
cancer, 5 years overall survival rate is still very poor (<15%)
[32]. Currently used treatment options for lung cancer include
chemotherapy drugs such as cisplatin, etoposide, irinotecan,
gemcitabine, and docetaxel. Emerging evidence indicates that
in lung cancer, a number of current anticancer therapies may
enrich stem-like cell subpopulations. For example, in NSCLC,
even a low dose cisplatin treatment signiﬁcantly enriches
CD1331 cells in H460 and H661 human NSCLC cell lines [32].
The presence of lung cancer SCs is usually evaluated by the
expression of variety of CSC markers [32]. A number of studies
have shown that the neuroendocrine cells in lung are the ori-
gin of lung CSCs and as such lung CSCs are highly responsive
to neuropeptides. For example, Sarvi et al., study suggests that
neuropeptide antagonists inhibit the tumor growth and selec-
tively target the chemoresistant CD1331 cells and inhibit tumor
growth [81]. Likewise, triﬂuoperazine is a well-known antipsy-
chotic drug that downregulates CD44 and CD133, and inhibits
tumor growth and spheroid formation in lung cancer both in
vitro and in vivo [82]. Combining triﬂuoperazine with conven-
tional geﬁtinib or cisplatin could make the enriched CD1331/
CD441 lung stem-like cells responsive to therapy and downre-
gulate gene signatures of drug resistance. Indeed, in mouse
models of geﬁtinib-resistant CL97-L2G tumors, the combination
of geﬁtinib with triﬂuoperazine suppressed tumorigenesis and
exhibited the lowest tumor burden [82].
As with the other types of epithelial derived tumor, an elevat-
ed level of Notch is also associated with poor outcomes in NSCLC.
Upregulation of Notch genes like Notch1, Notch2 and Hes-1 has
been observed in CD1331 NSCLC cells [32]. The cisplatin-induced
enrichment of CD1331 cells as mentioned before is also mediat-
ed through Notch signaling. A number of Notch inhibitors have
been developed to decrease the ALDH1 components in lung
cancer cells. The major Notch inhibitors in clinical analysis are the
g-secretase inhibitors. These inhibitors prevent release of intra-
cellular domain into the cytoplasm and subsequent translocation
to nucleus, thus inhibiting the Notch activation [83]. g-secretase
inhibitors like DAPT, MRK-003, and RO4929097 signiﬁcantly
decreased cisplatin-induced expression of transporter proteins
ABCG2 and ABCB1 in lung cancer. This may be why these inhibi-
tors increase sensitivity to cytotoxic drugs, particularly doxorubi-
cin and paclitaxel [34]. Furthermore, Arasada et al., has also
reported that g-secretase inhibitors can reverse erlotinib enrich-
ment of ALDH1 cells in EGFR mutated lung cancer cell lines [83].
The Hh pathway has also been implicated in chemothera-
py resistance in lung cancer and maintenance of lung CSCs
[84]. The monoclonal antibody 5E1 directed against Shh-N
inhibited the Hh signaling and decreased tumorigenicity in
H249 and H1618 SCLC cell lines both in vitro and in tumor
xenotransplants in nude mice [32]. Wnt inhibitors such as
XAV-939, IWR-1, and Wnt-2 monoclonal antibody have been
shown to downregulate canonical Wnt signaling and showed
antitumor activity and induced apoptosis in NSCLC cells [35,
85]. Likewise, EMT was reversed by inhibitors such as PHA-
665752 and PF-2341066 that blocked Met receptor phosphor-
ylation in chemoresistant SCLC. The combination of etoposide
and PF-2341066 showed a signiﬁcantly decreased in tumor
growth in previously resistant lung cancer cells [86].
In a study comparing salinomycin to paclitaxel, salinomy-
cin showed inhibition of both tumorsphere formation and
expression of ALDH, SOX2, CXCR4, and SDF-1 in lung adeno-
carcinoma A549 stem-like cells [22]. Even though paclitaxel
initially decreases tumor volume, progressive treatment
causes an increase in SC markers levels such as ALDH, CXCR4,
and SDF-1 and promotes metastatic spread in in vivo models.
However, this drug still requires further studies to address its
efﬁcacy in clinical settings [87].
It has been reported that stem cell factor (SCF) and its
receptor c-kit have major role in lung CSCs and blocking SCF-
c-kit leads to the inhibition of CSC proliferation and survival
induced by chemotherapy [88]. Upon combination, however
with cisplatin, this can eliminate both CSCs and bulk tumor
growth in the heterogeneous tumor population [89].
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Table 2. Drugs that are currently under evaluation to target (a) breast cancer, (b) colorectal cancer, (c) lung cancer, and (d) pancreatic
cancer stem-like cells
Compound Molecular structure References
(a) Breast cancer
3-OMF
(Pubchem CID: 10548301)
[25]
EGCG and its synthetic analogs
(Pubchem CID: 65064)
[3, 31]
Imetelstat [95]
Repertaxin
(PubChem CID: 9838712)
[24, 65, 66]
Tranilast
(PubChem CID: 5282230)
[3, 97]
(b) Colorectal cancer
BBI-608,
Napabucasin
PubChem CID: 10331844
[36]
Curcumin
PubChem CID: 969516
[30, 42, 78]
Genistein
PubChem CID: 5280961
[33]
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Table 2. Continued
Compound Molecular structure References
LGK974
PubChem CID: 46926973
[36]
PTC-209
PubChem CID: 1117196
[44, 75]
RO4929097
PubChem CID: 49867930
[34]
Resveratrol
PubChem CID: 445154
[46, 98]
Romidepsin
PubChem CID: 57515973
[71]
Salinomycin
PubChem CID: 6473797
[22, 53]
Vorinostat
PubChem CID: 5311
[71]
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Table 2. Continued
Compound Molecular structure References
WIKI4
PubChem CID: 2984337
[32]
XAV939
PubChem CID: 2726824
[99]
(c) Lung cancer
IWR-1-endo
PubChem CID: 91885421
[32]
LDE-225,
Sonidegib
PubChem CID: 24775005
[34, 35]
RO4929097
PubChem CID: 49867930
[34]
Vismodegib
PubChem CID: 24776445
[3, 48]
VS-6063,
Defactinib
PubChem CID: 25117126
Clinical Trials identiﬁer:
NCT01951690
(d) Pancreatic cancer
Catumaxomab Antibody [3]
Cyclopamine
PubChem CID: 442972
[3, 29, 93]
[31, 95]
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Recently, targeting ABC transporters with low molecular
weight heparin (LMWH) has received much interest, particu-
larly in the ﬁeld of drug resistance. ABC transporters pump
chemotherapeutic drugs out of the cell, conferring to resis-
tance to chemotherapy. LMWH has been shown to reduce
ABCG2 expression in six human lung cancer cell lines (REF).
Such approach also induced apoptosis and eliminated CSCs
when used in combination with cisplatin [90].
Telomerase has recently been demonstrated to be an
essential factor for CSC immortalization [91]. Treatment with
MST312, a telomerase inhibitor, signiﬁcantly reduced the
ALDH1 CSC population and the length of the telomeres in
these cells in vivo. MST312 has also been shown to induce
p21, p27, and apoptosis in the whole tumor population in
lung cancer [92]. As outlined above, recent progress in strate-
gies in treatment-resistant lung cancer cells and the signaling
cascades activated by CSCs are becoming increasingly impor-
tant for monitoring the progress of cancer therapy and for
evaluating new therapeutic approaches.
PANCREATIC CANCER
In the development of pancreatic cancer, the Hh pathway
plays an important rate-limiting role, and small molecule
antagonists targeting the Hh pathway demonstrated a signiﬁ-
cant inhibition of metastasis in xenografts derived from
human pancreatic cancer cell lines and pancreatic CSCs [53].
For example, vismodegib inhibits expression of Patched1,
Patched2, and Smo, key components of the Hh pathway. Even
though vismodegib only marginally affects tumor size initially,
it signiﬁcantly reduces the ALDH1 cell population with stem
cell properties eventually [93]. Another Hh pathway inhibitor,
cyclopamine acts synergistically with gemcitabine to reduce
the ALDH1 population in pancreatic CSCs. The combination of
cyclopamine and gemcitabine or combinations of cyclopamine
and rapamycin with chemotherapy have been shown to
decrease the proportion of CSCs in pancreatic cancer xeno-
graft models [93]. Green tea epigallocatechin-3-gallate (EGCG)
also has inhibitory effects on Hh pathway receptors Smo,
Patched, Gli1 and Gli2. In pancreatic CSCs, EGCG inhibits a
number of pluripotency-maintaining transcription factors such
as Nanog, c-Myc, and Oct4, therefore efﬁciently targeting
CSCs [48]. A plant-derived ﬂavonoid, quercetin, is also effec-
tive in inhibiting proliferation, self-renewal and EMT as well as
in inducing apoptosis of pancreatic CSCs without causing any
distinct toxicity to normal cells [94].
The telomerase inhibitor imetelstat causes telomere short-
ening and inhibition of telomerase in PANC1 pancreatic cancer
cells and prolonged treatment with imetelstat resulted in
reduced CSCs from bulk tumor cells in tumor engraft xeno-
graft studies [95]. Likewise, salinomycin in combination with
gemcitabine was reported to be more effective in eliminating
pancreatic CSCs in xenografted mice more than either
Table 2. Continued
Compound Molecular structure References
Epigallocatechin gallate
(EGCG) and its synthetic analogs
(Pubchem CID: 65064)
LDE-225*
PubChem CID: 24775005
[34, 35]
Metformin
PubChem CID: 4091
[37, 38]
MT110 Antibody [40]
VS-4718
PubChem CID: 25073775
Clinical Trials identiﬁer:
NCT02651727
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salinomycin or gemcitabine alone [22]. Salinomycin inhibited
the growth of CD133-expressing CSCs in tumorspheres while
gemcitabine inhibited the growth of CD133-negative non-
CSCs. Hence, the combination shows more potential in treat-
ing human pancreatic cancer than single agents [22].
Like in many other types of cancer, metformin targets
self-renewal in pancreatic CSCs and interferes with some key
transcription factors for CSC maintenance, such as Notch1,
Nanog, Oct4, and EZH2 [38]. It decreases the mRNA levels of
these factors and causes re-expression of the miRs of let-7
and miR-200 family, which are lost in pancreatic CSCs. All
these effects eventually inhibit CSC proliferation, self-renewal,
migration and invasion in pancreatic CSCs [38]. Moreover, in
pancreatic CSCs derived from human primary tumors,
resveratrol-induced apoptosis and resensitization, inhibited
EMT, and suppressed self-renewal capacity accompanied by
downregulation of Bcl-2, XIAP, Zeb-1, Slug, Snail, ABCG2,
Nanog, Sox-2, c-Myc, and Oct4 [96]. Consistent with these
effects, resveratrol also exhibited a reduction in pancreatic
tumor growth in KrasG12D mice [96].
Sulforaphane also induces apoptosis and prevents tumor-
sphere formation in pancreatic cancer cells. It speciﬁcally
binds to the transcriptionally active NF-jB complexes and
inhibits NF-jB-mediated anti-apoptotic signaling in CD241
CD442 pancreatic CSCs [47].
Table 2 shows the summery of these key compounds or
drugs currently being evaluated for the abovementioned CSCs.
CONCLUSION
Many advances have been made in the ﬁeld of targeted ther-
apy for CSCs. So far, approaches identiﬁed have included tar-
geting speciﬁc markers or signaling pathways to eliminate the
CSCs, altering their microenvironment, or reprogramming
CSCs for differentiation, re-sensitization to chemotherapy,
apoptosis, and reversal of EMT or to reduce metastasis. How-
ever, bringing evaluating these approaches in a clinical setting
remains a challenge.
For example, not all CSCs express markers. There may also
be non-CSC cancer cells that express the markers [20]. Hence,
CSC populations are constantly being rationalized and revised
for the identiﬁcation of new markers. Questions about opti-
mum mechanisms to target in different stages of cancer or
the extent to which surface markers can be justiﬁed enough
to distinguish CSC populations still remain to be addressed. In
this context, there is a need to further develop new methods
and improve existing models for isolating, identifying and tar-
geting CSCs. The recent advent of culturing of three-
dimensional (3D) spheres and organoids in a dish that allow
both normal and cancer stem cells to grow as they would do
in live organisms, can address CSCs associated gene(s) func-
tions and their use in CSC speciﬁc drug screening and drug
resistance studies [100–102]. It is also important to develop
well-deﬁned microenvironments for 3D spheroid and organoid
culture with intricate cell-cell and cell-matrix. Such tools can
then be exploited in successfully inducing CSCs differentiation
to reprogram toward a more differentiated phenotype cancer
cells. On the other hand, increasing evidence suggests that
combination therapies targeting both CSC and differentiated
cancer cells will be more effective [17]. Successful designing
of innovative targeting strategies, evaluating clinical efﬁcacy,
risk-beneﬁt ratio, and preclinical toxicity of the newly identi-
ﬁed drugs will also be required in this regard.
New approaches will increasingly require combinations of
targeting strategies against CSCs. These may include manipu-
lating CSC programming by differentiation-inducing agents or
chemo-sensitizing agents and combining them with conven-
tional chemotherapy drugs to eliminate cancer cells. Such
combinations would exert the antitumor effect more selec-
tively with minimum effects on normal cells. Future clinical
trials must be designed with competitive biological and clini-
cal endpoints with the aim of providing highly effective thera-
pies in patients with all stages of cancer.
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